Prediction Model for Response to Biologics and Small Molecular Agent for UC
Recruiting · NCT05186623 · Observational (researchers observe without assigning treatment) · Lead sponsor: Asan Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
Vedolizumab, Ustekinumab, or Tofacitinib
What this trial is about
This prospective observational study is going to develop and validate a prediction model of response to biologic agents and small molecular agents for Korean patients with ulcerative colitis.
Who can take part
Age range
18 Years to 79 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients with an established diagnosis of ulcerative colitis based on clinical symptoms, endoscopic features and histopathologic features
- Patients who are going to receive vedolizumab, ustekinumab, or tofacitinib treatment
Exclusion criteria
- Not Korean ethnicity by family history
- Inflammatory Bowel Disease Unclassified
- Patients who already received colectomy due to ulcerative colitis
Where it is running
1 location listed.
- Asan Medical Center - Seoul, South Korea